Licensing Deal Signals Progress for Novel RA Treatment

Subscribe today to listen to this content Get Access

Rheumatoid arthritis (RA) may be an autoimmune disease, but its collateral damage — erosion of cartilage, joint deformity, and synovial hypertrophy — lands squarely in orthopedic territory.

And now, a new small-molecule contender is entering the race to protect those joints before surgeons ever need to replace them.